Fitch: Generic Copaxone Approval Could Prompt Losses At Teva - Fitch Research

Fitch: Generic Copaxone Approval Could Prompt Losses At Teva

Fitch: Generic Copaxone Approval Could Prompt Losses At Teva - Fitch Research
Fitch: Generic Copaxone Approval Could Prompt Losses At Teva
Published Apr 17, 2015
739 words — Published Apr 17, 2015
Price US$ 149.00  |  Buy this Report Now

About This Report

  
Brief Excerpt:

Fitch: Generic Copaxone Approval Could Prompt Losses At Teva 17 Apr 2015 2:30 PM (EDT) Fitch Ratings-New York-17 April 2015: The overhanging risk of generic competition to Copaxone could prompt material top-line and profit losses at...

  
Report Type:

Press Release

Company(ies)
Teva Pharmaceutical Industries Ltd. , Teva Pharmaceuticals USA Inc.
Ticker(s)
TEVA
Issuer
Teva Pharmaceuticals USA, Inc.
Format:
HTML HTML
Buy Now

Fitch Research—Fitch Ratings is a leading global rating agency committed to providing the world's credit markets with independent, timely and prospective credit opinions. Built on a foundation of organic growth and strategic acquisitions, Fitch Ratings has grown rapidly during the past decade gaining market presence throughout the world and across all fixed income markets.

About the Author


Cite this Report

  
MLA:
Fitch Research. "Fitch: Generic Copaxone Approval Could Prompt Losses At Teva" Apr 17, 2015. Alacra Store. May 14, 2025. <http://www.alacrastore.com/fitch-credit-research/Fitch-Generic-Copaxone-Approval-Could-Prompt-Losses-At-Teva-983157_pr_frame>
  
APA:
Fitch Research. (). Fitch: Generic Copaxone Approval Could Prompt Losses At Teva Apr 17, 2015. New York, NY: Alacra Store. Retrieved May 14, 2025 from <http://www.alacrastore.com/fitch-credit-research/Fitch-Generic-Copaxone-Approval-Could-Prompt-Losses-At-Teva-983157_pr_frame>
  
US$ 149.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.